Gene Ontology and Expression Studies of Strigolactone Analogues on a Hepatocellular Carcinoma Cell Line

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Human hepatocellular carcinoma (HCC) is a prevalent and recurring liver cancer with limited effective treatments.
• Plant-derived compounds offer potential anticancer strategies by targeting cellular signaling pathways.
• Strigolactone (SL) analogues, including TIT3, have demonstrated anticancer properties in various cancer cell lines.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying the anticancer activity of the novel strigolactone analogue TIT3 in HepG2 human hepatocellular carcinoma cells.
• To identify specific genes and pathways modulated by TIT3 treatment in HCC.

Main Methods:

• RNA sequencing (RNA-Seq) was employed to analyze gene expression profiles in HepG2 cells treated with TIT3.
• Differential gene expression analysis was performed to identify significantly altered genes.
• Bioinformatic tools were utilized for data analysis and interpretation.

Main Results:

• TIT3 significantly downregulated genes involved in microtubule organization (e.g., TUBB, BUB1B) and DNA repair (e.g., RAD51, RAD52).
• Epigenetic modulators (e.g., UHRF1, HDAC7, DNMT1) were also downregulated by TIT3.
• Pro-apoptotic genes (e.g., CASP3, TNF-α, CASP7, CDKN1A) were significantly upregulated, indicating induction of programmed cell death.

Conclusions:

• TIT3 exhibits antiproliferative and proapoptotic effects on HCC cells through modulation of microtubule organization, epigenetic regulation, and DNA repair pathways.
• The findings suggest that TIT3 may represent a promising therapeutic candidate for the treatment of hepatocellular carcinoma.
• Further investigation into the signaling pathways targeted by TIT3 is warranted.